Table 2.
Therapeutic history, according to the period of life of HIV-1 acquisition: in the perinatal period (P) or in adulthood (A), stratified on duration of HIV infection at the time of the latest viral load measurement (between 2012 and 2018)–the French ANRS Coverte, CO10-EPF, Primo Seropri, Copana cohorts.
| Duration of HIV infection | 2–5 years |
6–12 years |
13–17 years |
18–24 years |
25–32 years |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P-HIV N = 17 | A N = 472 | p-value | P N = 49 | A N = 703 | p-value | P N = 81 | A N = 210 | p-value | P N = 73 | A N = 82 | p-value | P N = 90 | A N = 48 | p-value | |
| FEATURES AT FIRST ART | |||||||||||||||
| Time since HIV infection, months | |||||||||||||||
| Median | 4.6 | 1.4 | e | 4.2 | 15.5 | f | 2.8 | 1.9 | 8.2 | 1.6 | f | 17.0 | 80.6 | f | |
| IQR | (3.4–14.4) | (1.1–2.4) | (1.4–13.9) | (1.9–36.9) | (1.4–6.8) | (1.2–24.7) | (2.7–20.4) | (1.2–3.8) | (6.0–42.0) | (47.6–98.5) | |||||
| Year of initiation | |||||||||||||||
| Median | 2013 | 2013 | 2007 | 2009 | f | 1999 | 2002 | f | 1994 | 1997 | f | 1991 | 1995 | f | |
| IQR | (10–13) | (12–14) | (05–08) | (07–10) | (97–2002) | (00–04) | (93–95) | (96–98) | (89–92) | (92–97) | |||||
| 1st ART Regimen | |||||||||||||||
| INSTI, or entry inhibitor (±NRTI) | 5.9 (1) | 25.2 (119) | 0.0 (0) | 13.4 (94) | f | 0.0 (0) | 1.4 (3) | f | 0.0 (0) | 1.2 (1) | f | 0.0 (0) | 0.0 (0) | ||
| PI and NNRTI (±NRTI) | 0.0 (0) | 0.0 (0) | 4.1 (2) | 0.4 (3) | 6.2 (5) | 3.3 (7) | 0.0 (0) | 0.0 (0) | 0.0 (0) | 0.0 (0) | |||||
| PI (±NRTI) | 76.5 (13) | 61 (288) | 69.4 (34) | 58.2 (409) | 39.5 (32) | 67.1 (141) | 2.7 (2) | 73.2 (60) | 6.7 (6) | 14.6 (7) | |||||
| NNRTI (±NRTI) | 17.6 (3) | 13.6 (64) | 18.4 (9) | 27.2 (191) | 7.4 (6) | 21.9 (46) | 2.7 (2) | 3.7 (3) | 1.1 (1) | 2.1 (1) | |||||
| Only NRTIs | 0.0 (0) | 0.2 (1) | 8.2 (4) | 0.9 (6) | 46.9 (38) | 6.2 (13) | 94.5 (69) | 22.0 (18) | 92.2 (83) | 83.3 (40) | |||||
| CD4% | |||||||||||||||
| Median | 45.0 | 27.0 | c | 32.0 | 22.0 | d | 36.0 | 22.0 | f | 34.0 | 26.0 | d | 28.0 | 18.0 | e |
| IQR | (22.0–56.5) | (20.0–34.0) | (16.0–49.0) | (17.0–27.0) | (23.0–49.0) | (16.0–29.0) | (20.0–43.0) | (18.0–30.0) | (18.0–39.0) | (12.0–24.0) | |||||
| VL at ART initiation (log10 copies/mL) | |||||||||||||||
| Median | 5.8 | 5.3 | 5.4 | 4.9 | 5.2 | 5.1 | 4.8 | 5.0 | 4.8 | 4.3 | |||||
| IQR | (5.3–6.6) | (4.6–6.1) | (3.9–6.1) | (4.3–5.4) | (4.0–5.8) | (4.5–5.7) | (4.4–5.2) | (4.3–5.7) | (4.2–5.0) | (3.9–4.8) | |||||
| FEATURES AT LATEST EVALUATION | |||||||||||||||
| Time since 1st ART (years) | |||||||||||||||
| Median | 4 | 3.5 | c | 9.4 | 7.0 | f | 16.2 | 14.0 | f | 22.4 | 19.1 | f | 25.6 | 20.9 | f |
| IQR | (3.6–5.0) | (2.5–4.4) | (8.0–10.6) | (5.8–9.0) | (14.3–17.1) | (12.9–15.4) | (20.2–23.3) | (18.4–20.0) | f | (24.0–27.1) | (19.1–24.2) | ||||
| Time since first combined therapya(years) | |||||||||||||||
| Median | 4.0 | 3.5 | c | 9.3 | 7.0 | f | 14.5 | 13.8 | c | 16.7 | 18.8 | f | 18.4 | 18.7 | |
| IQR | (3.6–5.0) | (2.5–4.4) | (7.9–10.6) | (5.7–8.9) | (12.8–16.0) | (11.8–15.2) | (14.1–18.5) | (17.9–19.5) | (15.4–19.8) | (17.3–19.9) | |||||
| Number of different ART regimens | |||||||||||||||
| Median | 3 | 2 | 3 | 3 | 5 | 5 | 9 | 5 | f | 12 | 9 | ||||
| IQR | (1–3) | (1–3) | (2–4) | (2–4) | (4–7) | (3–7) | (8–12) | (4–8) | (8–14) | (6–15) | |||||
| Nadir CD4%b | |||||||||||||||
| Median | 25.0 | 32.0 | d | 22.0 | 25.0 | 17.0 | 19.0 | d | 14.6 | 20.5 | d | 11.0 | 13.5 | ||
| IQR | (22.0–31.0) | (27.0–37.0) | (17.0–29.0) | (20.0–30.0) | (11.0–23.0) | (15.0–25.0) | (6.0–22.4) | (14.0–26.0) | (4.4–21.0) | (7.0–20.5) | |||||
| Year of initiation of last ART regimen, % (n) | |||||||||||||||
| ≤2006 | 0.0 (0) | 0.0 (0) | 12.2 (6) | 2.7 (19) | e | 8.6 (7) | 8.1 (17) | 0.0 (0) | 17.1 (14) | e | 2.2 (2) | 14.6 (7) | e | ||
| 2007–2013 | 35.3 (6) | 34.1 (161) | 55.1 (27) | 53.9 (379) | 53.1 (43) | 54.8 (115) | 50.7 (37) | 36.6 (30) | 32.2 (29) | 47.9 (23) | |||||
| 2014–2017 | 64.7 (11) | 65.9 (311) | 32.7 (16) | 43.4 (305) | 38.3 (31) | 37.1 (78) | 49.3 (36) | 46.3 (38) | 65.6 (59) | 37.5 (18) | |||||
| Last ART regimen, % (n) | |||||||||||||||
| INSTI, or entry inhibitor (+NRTI) | 11.8 (2) | 41.9 (198) | d | 12.2 (6) | 32.7 (230) | f | 14.8 (12) | 29.0 (61) | f | 37.0 (27) | 30.5 (25) | d | 62.6 (59) | 33.3 (16) | f |
| PI and NNRTI (±NRTI) | 0.0 (0) | 0.2 (1) | 2.0 (1) | 1.3 (9) | 3.7 (3) | 1.4 (3) | 1.4 (1) | 2.4 (2) | 2.2 (2) | 0.0 (0) | |||||
| PI (±NRTI) | 58.8 (10) | 20.6 (97) | 59.2 (29) | 18.1 (127) | 51.9 (42) | 14.3 (30) | 35.6 (36) | 18.3 (15) | 18.9 (17) | 18.8 (9) | |||||
| NNRTI (±NRTI) | 29.4 (5) | 36.4 (172) | 26.5 (13) | 46.9 (330) | 27.2 (22) | 54.3 (114) | 26.0 (19) | 43.9 (36) | 13.3 (12) | 27.1 (13) | |||||
| Only NRTIs | 0.0 (0) | 0.8 (4) | 0.0 (0) | 1.0 (7) | 2.5 (2) | 1.0 (2) | 0.0 (0) | 4.9 (4) | 0.0 (0) | 20.8 (10) | |||||
| Calendar period of latest VLmeasurement, % (n) | |||||||||||||||
| 2012–2013 | 5.9 (1) | 5.7 (27) | 14.3 (7) | 7.3 (51) | c | 29.6 (24) | 5.2 (11) | f | 6.9 (5) | 8.5 (7) | 1.1 (1) | 8.3 (4) | c | ||
| 2014–2015 | 17.7 (3) | 10.6 (50) | 20.4 (10) | 11.4 (80) | 27.2 (22) | 13.3 (28) | 17.8 (13) | 8.5 (7) | 10.0 (9) | 20.8 (10) | |||||
| 2016–2018 | 76.5 (13) | 83.7 (395) | 65.3 (32) | 81.4 (572) | 43.2 (35) | 81.4 (171) | 75.3 (55) | 82.9 (68) | 88.9 (80) | 70.8 (34) | |||||
Values in bold are median or percentages.
ART: antiretroviral therapy, VL: plasma viral load, INSTI: Integrase Strand Transfer Inhibitor, PI: Protease Inhibitor, NNRTI: Non-Nucleoside Reverse Transcriptase Inhibitor, NRTI: Nucleoside Reverse Transcriptase Inhibitor.
a
Defined as the concomitant use of ≥3 drugs from ≥2 classes of antiretroviral drugs (for 5 patients, the date of initiation of first combined therapy was unknown).
b
After initiation of ART.
c
p ≤ 0.05.
d
p ≤ 0.01.
e
p ≤ 0.001.
f
p ≤ 0.0001.